BioNTech enters one of its most consequential weeks in recent memory, juggling a freshly approved COVID-19 vaccine, a deepening patent litigation campaign on two fronts, and second-quarter earnings due Tuesday that could reshape the investment narrative. The Mainz-based biotech finds itself simultaneously as plaintiff and defendant in disputes that could determine whether its intellectual property becomes a revenue engine or a costly liability.
The stock, trading around €80, has been drifting below its 200-day moving average, reflecting investor caution as the company transitions from pandemic windfall to endemic-market realities. The shares sit roughly 24 percent off their January high of €105.80, with the market seemingly unwilling to award credit for either the vaccine approval or the company’s legal offensive until the financial picture clarifies.
EU Approval Arrives as Revenue Forecasts Falter
The European Commission has cleared BioNTech’s monovalent COVID-19 vaccine adapted for the XFG Omicron sublineage, covering the 2026/2027 season. The shot, targeting the JN.1 lineage and authorized for patients six months and older, received approval across all 27 EU member states plus Iceland, Liechtenstein, and Norway, following a European Medicines Agency recommendation on July 23. Immunogenicity data demonstrated robust responses against multiple circulating variants, including XFG.1.1, NB.1.8.1, and PQ.17. BioNTech has already commenced production at its own risk to ensure deliveries begin in the third quarter.
Management projects €4.2 billion in revenue for the 2026/2027 vaccine cycle at a 68 percent gross margin, giving the company a planning anchor after a bruising financial year. Yet the market’s muted reaction — the stock edged up just 0.19 percent on the news — suggests investors are weighing this against persistent analyst skepticism. Morgan Stanley recently trimmed its price target to $119, citing COVID vaccine revenue forecasts that lag expectations, though the broader consensus target of €106.38 still implies meaningful upside from current levels.
A Two-Front Patent War
The legal calendar is equally demanding. BioNTech has sued Moderna in Delaware federal court, alleging that Moderna’s mNEXSPIKE vaccine infringes its patented mRNA technology. The stakes are substantial: BioNTech’s complaint asserts that mNEXSPIKE will account for roughly 55 percent of Moderna’s total COVID vaccine revenue during the 2025/2026 respiratory season. Moderna has pledged a vigorous defense.
Simultaneously, BioNTech and partner Pfizer sit on the defensive side of a separate dispute. Arbutus Biopharma and its licensee Genevant accuse the pair of using proprietary lipid nanoparticle technology. The pressure intensified after Moderna settled its similar fight with Arbutus and Genevant in March 2026 — paying $950 million upfront with a further $1.3 billion contingent on an appeal — a deal that covered only Moderna and freed the plaintiffs to press harder against Pfizer and BioNTech.
A Markman ruling in September 2025 already favored Genevant and Arbutus, and the plaintiffs escalated in July 2026 with three new international lawsuits, including proceedings before the Unified Patent Court in Europe. Roivant’s chief executive, whose company controls Genevant, has been explicit about the strategy: the Moderna settlement validates the patent portfolio, injects substantial liquidity, and provides a springboard for pursuing Pfizer and BioNTech.
Should investors sell immediately? Or is it worth buying BioNTech?
The scale of exposure is the crux. Comirnaty, the joint Pfizer-BioNTech vaccine, represents roughly two-thirds of global COVID mRNA vaccine sales — a revenue base far larger than Moderna’s. Any settlement or damages award could plausibly exceed the $2.25 billion benchmark set by Moderna’s agreement.
The Financial Backdrop
The company’s latest annual results illustrate the cost of the pandemic-to-endemic transition. Revenue for 2025 came in at €2,869.9 million, while the net loss widened to €1,136.1 million — a stark swing from the €930.3 million profit recorded in 2023. Despite the red ink, BioNTech maintains a fortress balance sheet with €7,675.4 million in cash and €19,224.2 million in equity at year-end. Auditor EY issued an unqualified opinion but flagged critical audit matters including COVID revenue recognition, the Bristol Myers Squibb collaboration, ongoing litigation, and intangible asset valuations.
A third legal front adds further complexity: Bayer has sued Moderna, Pfizer, BioNTech, and Johnson & Johnson over a US patent covering a technique to reduce polyadenylation signals in mRNA therapeutics. Patent attorneys expect this dispute to drag on, consuming management bandwidth that might otherwise focus on the oncology pipeline — the franchise meant to carry BioNTech’s long-term growth story.
Tuesday’s Numbers
The immediate catalyst arrives Tuesday with second-quarter results. The first quarter showed a mixed picture: a loss per share of $2.10 beat the $2.26 consensus estimate, but revenue of $118.10 million fell roughly 30.7 percent short of the $170.33 million analysts had projected, triggering a 3.88 percent share decline. For Q2, the Street expects a loss per share of $2.13 on revenue of $160.90 million.
BioNTech has been spending aggressively to diversify beyond vaccines. The Biotheus acquisition carried an upfront payment of approximately $800 million, roughly €694 million, while the CureVac deal was valued at around $1.25 billion on an equity basis, approximately €1,085 million. Both transactions aim to bolster the cancer immunotherapy pipeline, which alongside the vaccine business forms the company’s second strategic pillar. As of June 30, 251,204,366 BioNTech shares were outstanding.
The sequencing of legal outcomes will likely prove decisive. If BioNTech’s offensive case against Moderna yields licensing income before the defensive Genevant/Arbutus matter reaches a settlement or judgment, the financial calculus shifts favorably. But with the Unified Patent Court cases and the Delaware proceedings advancing in parallel, and Comirnaty’s far larger revenue base setting the stage for potentially outsized damages, the risk skew appears tilted toward a meaningful financial hit. Until the litigation picture clarifies, procedural updates from the European and US courts may provide more concrete trading signals than the vaccine cycle itself.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 31 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 31.
BioNTech: Buy or sell? Read more here...
